Halozyme Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell HALO and other ETFs, options, and stocks.

About HALO

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. 

CEO
Helen I. Torley
CEOHelen I. Torley
Employees
423
Employees423
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1998
Founded1998
Employees
423
Employees423

HALO Key Statistics

Market cap
7.99B
Market cap7.99B
Price-Earnings ratio
26.64
Price-Earnings ratio26.64
Dividend yield
Dividend yield
Average volume
1.62M
Average volume1.62M
High today
$68.59
High today$68.59
Low today
$67.14
Low today$67.14
Open price
$68.22
Open price$68.22
Volume
354.24K
Volume354.24K
52 Week high
$82.22
52 Week high$82.22
52 Week low
$47.50
52 Week low$47.50

Stock Snapshot

The current Halozyme Therapeutics(HALO) stock price is $67.72, with a market capitalization of 7.99B. The stock trades at a price-to-earnings (P/E) ratio of 26.64.

On 2026-03-10, Halozyme Therapeutics(HALO) stock moved within a range of $67.14 to $68.59. With shares now at $67.72, the stock is trading +0.9% above its intraday low and -1.3% below the session's peak.

Trading activity shows a volume of 354.24K, compared to an average daily volume of 1.62M.

The stock's 52-week range extends from a low of $47.50 to a high of $82.22.

The stock's 52-week range extends from a low of $47.50 to a high of $82.22.

HALO News

Simply Wall St 5d
Did Record ENHANZE Royalties and New Deals Just Shift Halozyme Therapeutics' Investment Narrative?

In recent weeks, Halozyme Therapeutics reported record 2025 revenue of about US$1.40 billion, highlighted growing ENHANZE-driven royalties, and outlined progres...

Did Record ENHANZE Royalties and New Deals Just Shift Halozyme Therapeutics' Investment Narrative?
Simply Wall St 7d
Halozyme Acquisitions And ENHANZE Growth Shape Long Term Valuation Story

Halozyme Therapeutics (NasdaqGS:HALO) has agreed to acquire Hypercon and several biotech startups, expanding its drug delivery and platform capabilities. The H...

Halozyme Acquisitions And ENHANZE Growth Shape Long Term Valuation Story

Analyst ratings

56%

of 9 ratings
Buy
55.6%
Hold
33.3%
Sell
11.1%

People also own

Based on the portfolios of people who own HALO. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.